ERVEBO
Biological
Merck Sharp & Dohme LLC
Total Payments
$136,275
Transactions
6
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $12,998 | 2 | 0 |
| 2023 | $122,478 | 2 | 0 |
| 2022 | $799.44 | 2 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $136,275 | 6 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Multicenter Study of the Immunogenicity of Recombinant Vesicular Stomatitis Vaccine for Ebola-Zaire rVSV G-ZEBOV-GP for Pre-Exposure Prophylaxis PREP In Individuals at Potential Occupational Risk for Ebola Virus Exposure | Merck Sharp & Dohme LLC | $136,275 | 0 |
Top Doctors Receiving Payments for ERVEBO
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Bethesda, MD | $136,275 | 6 |
Ad
Manufacturing Companies
- Merck Sharp & Dohme LLC $136,275
Product Information
- Type Biological
- Total Payments $136,275
- Total Doctors 0
- Transactions 6
About ERVEBO
ERVEBO is a biological associated with $136,275 in payments to 0 healthcare providers, recorded across 6 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme LLC.
Payment data is available from 2022 to 2024. In 2024, $12,998 was paid across 2 transactions to 0 doctors.
The most common payment nature for ERVEBO is "Unspecified" ($136,275, 100.0% of total).
ERVEBO is associated with 1 research study, including "A Multicenter Study of the Immunogenicity of Recombinant Vesicular Stomatitis Vaccine for Ebola-Zaire rVSV G-ZEBOV-GP for Pre-Exposure Prophylaxis PREP In Individuals at Potential Occupational Risk for Ebola Virus Exposure" ($136,275).